KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Research & Development: 2011-2024

Historic Research & Development for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $46.2 million.

  • Esperion Therapeutics' Research & Development rose 35.91% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 15.28%. This contributed to the annual value of $46.2 million for FY2024, which is 46.30% down from last year.
  • As of FY2024, Esperion Therapeutics' Research & Development stood at $46.2 million, which was down 46.30% from $86.1 million recorded in FY2023.
  • Esperion Therapeutics' Research & Development's 5-year high stood at $146.9 million during FY2020, with a 5-year trough of $46.2 million in FY2024.
  • Its 3-year average for Research & Development is $83.8 million, with a median of $86.1 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first increased by 12.22% in 2022, then tumbled by 46.30% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Research & Development stood at $146.9 million in 2020, then dropped by 27.88% to $106.0 million in 2021, then increased by 12.22% to $118.9 million in 2022, then dropped by 27.60% to $86.1 million in 2023, then crashed by 46.30% to $46.2 million in 2024.